Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in territories outside the United States,

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the companies said this morning.